The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | L | Antineoplastic and immunomodulating agents | |
| 2 | L01 | Antineoplastic agents | |
| 3 | L01F | Monoclonal antibodies and antibody drug conjugates | |
| 4 | L01FX | Other monoclonal antibodies | |
| 5 | L01FX18 |
| Active Ingredient | Description | |
|---|---|---|
| Amivantamab |
Amivantamab is a low-fucose, fully-human IgG1-based EGFR-MET bispecific antibody with immune cell-directing activity that targets tumours with activating EGFR Exon 20 insertion mutations. Amivantamab binds to the extracellular domains of EGFR and MET. Amivantamab disrupts EGFR and MET signalling functions through blocking ligand binding and enhancing degradation of EGFR and MET, thereby preventing tumour growth and progression. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| RYBREVANT Concentrate for solution for infusion | European Medicines Agency (EU) | MPI, EU: SmPC | |
| RYBREVANT Solution for injection | MPI, US: SPL/PLR |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
